Evaluation of the Natural History of Patients With Tumors of the Central Nervous System
This protocol is designed to evaluate patients with tumors of the central nervous system
(CNS) who appear to be probable candidates for future protocol entry or have disease
manifestations that are of unique scientific interest, importance, and/or educational value.
To evaluate patients with tumors of the central nervous system (CNS) who are probable future
candidates for NCI Phase I and II protocols.
To follow patients with tumors of the CNS that are representative of important scientific
and/or clinical principles.
To allow a steady flow of patients with tumors of the CNS at the NIH for the purpose of
educating nurses, medical students, residents, clinical fellows, and physicians in the
management and care of this specialized subgroup of cancer patients.
All patients greater than or equal to 12 months of age with tumors of the CNS of interest to
the NOB, who may be candidates for another NOB trial at some point in the future.
Patients with tumors of the CNS that are of particular interest to members of the NOB
because they pose important clinical and/or scientific questions and/or shed light on
important aspects of the disease.
Patients with tumors of the CNS who offer an important educational benefit to neuro-oncology
trainees and staff.
Ability of subject or Legally Authorized Representative (LAR) to understand and the
willingness to sign a written informed consent document. Availability of a parent or legal
guardian to give informed consent for children.
All patients will undergo an initial evaluation at the Clinical Center by a member of the
NOB where past medical and oncologic histories will be obtained as well as relevant data
such as neuroimaging and pathology review. A total of 3,000 patients will be accrued to this
Patients may be seen at the NIH Clinical Center at varying intervals depending on the
clinical situation but data related to the natural history of their disease course and
outcome will be collected at least every six months.
Teri N Kreisl, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|